There are 2789 resources available
1312P - Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
Presenter: Giacomo Pelizzari
Session: ePoster Display
1380P - Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
Presenter: Geoffrey Ku
Session: ePoster Display
1292P - Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)
Presenter: Ryo Toyozawa
Session: ePoster Display
1294P - 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
Presenter: Filippo Dall'Olio
Session: ePoster Display
1256P - Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
Presenter: Rebecca Heist
Session: ePoster Display
1257P - Effect of hepatic impairment on tepotinib pharmacokinetics
Presenter: Thomas Marbury
Session: ePoster Display
1258P - MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study
Presenter: Hélène Babey
Session: ePoster Display
1333P - Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
Presenter: Go Saito
Session: ePoster Display